Page 2 - CUA2019 Abstracts - Oncology-Prostate

Poster session 4: Prostate Cancer I

Results: Kaplan-Meier analyses showed that patients with a higher fre- MP-4.5
quency of nuclear p65 had an increased risk of progression (biochemical Expression of EGFR-ERBB2-ERBB3 demonstrates a potential to
relapse and bone metastasis development) and mortality (p<0.05). When predict prostate cancer relapse or bone metastasis development
combined with preoperative prostate-specific antigen (PSA), Gleason Sylvie Clairefond , Véronique Ouellet , Benjamin Péant , Véronique
1,2
1,2
1,2
grade, margin status, and pTNM, nuclear p65 expression remained sig- Barrès , Pierre Karakiewicz , Anne-Marie Mes-Masson 1,2,3 , Fred Saad 1,2,4
1,4
1,2
nificant in Cox regression analyses. Indeed, patients with higher level 1 Centre de Recherche du Centre Hospitalier de l’Université de Montréal,
of nuclear p65 presented an increase risk progression using three differ- Montréal, QC, Canada; Institut du Cancer de Montréal, Montréal, QC,
2
ent endpoints: biochemical relapse (hazard ratio [HR] 1.33; p=0.005), Canada; Département de Médecine, Université de Montréal, Montréal,
3
development of bone metastases (HR 1.82; p=0.033), and PCa-specific QC, Canada; Département de Chirurgie, Université de Montréal,
4
mortality (HR 2.63; p=0.033). Montréal, QC, Canada
Conclusions: We report the first study using the pan-Canadian multicen- Molecular Pathology Core Facility of the CRCHUM
tre cohorts of CPCBN and validate the association between increased Introduction: Prostate cancer (PCa) is the most frequently diagnosed can-
frequency of nuclear p65 expression and risk of disease progression. cer in men and the third leading cause of cancer-related mortality among
Reference men in Canada. PCa patient management varies widely, thus there is a
1. Ouellet V, Aprikian A, Bergeron A, et al. The Terry Fox Research need for reliable biomarkers to identify patients with poor prognosis and
Institute Canadian Prostate Cancer Biomarker Network: A descrip- to accurately stratify PCa for optimal treatment. Members of the ERBB
tive analysis of a pan-Canadian, multicentre cohort for biomarker family are involved in epithelium cancers and represent potential bio-
validation. BMC Urol 2018;18:78. https://doi.org/10.1186/s12894- markers for PCa. Our objective was to evaluate these proteins, separate
018-0392-x or combined, and correlate their expression with patient clinical data.
Methods: Immunofluorescence was performed on tissue microarrays
MP-4.4 (TMAs) composed of radical prostatectomy specimens (285 patients). The
Does time spent on active surveillance adversely affect the TMAs included two cores of benign tissue and two cores of tumour from
pathological and oncological outcomes in patients undergoing each patient. Quantification of biomarker expression was semi-automated
delayed radical prostatectomy? using the VisiomorphDP software. Correlation with patient clinical out-
Ardalan Ahmad , Patrick Richard , Narhari Timilshina , Maria come was determined using SPSS V25 and R V1.1.383 software.
1
1
1
Komisarenko , Girish S. Kulkarni , Robert Hamilton , Alexandre Zlotta , Results: Within benign glands, Kaplan-Meier analysis showed a significant
1
1
1
1
Neil E. Fleshner , Antonio Finelli association between high expression of EGFR or ERBB2 and an increased
1
1
1 Division Urology, Department Surgery, University Health Network, risk of developing a biochemical recurrence (BCR) (p=0.009 and p=0.022,
University of Toronto, Toronto, ON, Canada respectively). Patients expressing high levels of both EGFR and ERBB2 had
Introduction: The pathological and oncological outcomes of men under- the worst prognosis (p=0.004). Basing on a multivariate Cox regression
going radical prostatectomy (RP) following a period of active surveillance model, these proteins were strong predictive biomarkers of BCR. Within
(AS) for favourable-risk prostate cancer (PCa) is not well-established. We tumour cores, Kaplan-Meier analysis showed a significant association
aimed to asses pathological and oncological outcomes for men with between low ERBB2 or ERBB3 expression and the development of bone
favorable-risk PCa on AS progressing to RP for clinically significant PCa metastasis (p=0.003 and p=0.036, respectively). By including EGFR,
(Gleason group ≥2). ERBB2, and ERBB3 in a decision tree model, four groups are obtained
Methods: A prospectively maintained AS database at Princess Margaret to discriminate between patients at low and high risk of bone metastasis
Cancer Centre (PMCC) was queried to identify patients progressing to RP development (p<0.001).
(n=294) between 1992 and 2015. Patients undergoing RP for clinically sig- Conclusions: Our results show that two different combinations of these
nificant PCa were selected (ASRP, n=171). Clinical and pathological char- proteins are associated with poor patient outcome when using BCR or
acteristics at the time of progression to RP (age, prostate-specific antigen bone metastasis development as an endpoint. Currently, large-scale, mul-
[PSA], year of biopsy, Gleason score, and primary Gleason grade) were ticentre validation studies are ongoing.
used to compare pathological and oncological outcomes to a matched
cohort of patients treated with upfront RP at diagnosis (n=407). MP-4.6
Results: One hundred seventy-one patients underwent RP after a median Psychological morbidity associated with a new diagnosis of
of 31.0 months (interquartile range [IQR] 30.0–44.0) on AS. At RP, the prostate cancer: Rates and predictors of depressive symptoms
rate of pT3, pN1, and positive surgical margin rate were comparable in the RADICAL PC study
between ASRP and matched controls. The ASRP cohort had a smaller Gagan Fervaha , Jason Izard , Dean A. Tripp , Selina Rajan , Sarah
1
1
2
1
cancer volume and lower extraprostatic extension (EPE) and seminal ves- Karampatos , Bobby Shayegan , Edward D. Matsumoto , Tamim Niazi ,
3
3
2
4
icle invasion (SVI) rate. Median followup after RP was 4.9 (IQR 3.1–6.9) Annabel Chen-Tournoux , Vincent Fradet , Yves Fradet , Guila Delouya ,
7
8
6
5
years. Biochemical recurrence (BCR) occurred in 24 (14%) and 78 (19%) Daniel Taussky , Luke T. Lavallée , Christopher Johnson , Joseph L.
9
8
9
of ASRP and matched controls, respectively (p=0.14). At five years, the Chin , Darin Gopaul , Margot Davis , Jehonathan H. Pinthus , Darryl
3
11
10
12
BCR-free survival rate in the ASRP cohort and upfront RP cohort were P. Leong , D. Robert Siemens 1
2,3
85.6% and 79.2%, respectively (p=0.112). The retrospective, single-cen- 1 Department of Urology, Queen’s University, Kingston, ON, Canada;
tre nature of the study is a limitation. 2 Population Health Research Institute, Hamilton Health Sciences,
Conclusions: Curative-intent RP after a period of AS renders excellent Hamilton, ON, Canada; McMaster University, Hamilton, ON, Canada;
3
pathological and oncological outcomes at five years. Moreover, the delay 4 Department of Oncology, McGill University, Montréal, QC, Canada;
of therapy after a period of AS does not appear to result in inferior onco- 5 Department of Medicine, McGill University, Montréal, QC, Canada;
logical outcomes compared to patients with similar risk characteristics 6 Department of Surgery, CHU de Québec-Université Laval, Québec City,
undergoing upfront RP. QC, Canada; Université Laval, Québec City, QC, Canada; Department
8
7
of Radiation Oncology, Centre Hospitalier de l’Université de Montréal,
Montréal, QC, Canada; University of Ottawa, Ottawa, ON, Canada;
9
10 Division of Urology, Western University, London, ON, Canada;
11 Department of Radiation Oncology, Grand River Regional Cancer
12
Centre, Kitchener, ON, Canada; University of British Columbia,
Vancouver, BC, Canada; RADICAL PC Investigators
Introduction: Across all cancer sites and stages, prostate cancer has one
of the greatest median five-year survival rates. With this comes a focus
on survivorship issues following diagnosis and treatment. In the current
CUAJ • June 2019 • Volume 13, Issue 6(Suppl5) S105